Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL

EP: 1.RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

EP: 2.2014 ASH Annual Meeting

EP: 3.Two Experts Discuss JAK Inhibition in Polycythemia Vera

Now Viewing

EP: 4.Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL

Max S. Topp, MD, head of the Department of Hematology, University Hospital of Würzburg, in Würzburg, Germany, discusses the efficacy of the combination of glofitamab plus R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) from a phase 1 trial (NCT03467373) done in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).

Data from both the safety run-in portion and the expansion stage of the study were presented at the 2022 ASH Annual Meeting. All agents that comprised the R-CHOP regimen were administered at a categorized dose intensity of at least 90% in more than 90% of patients, except for vincristine, which was received at a dose intensity of at least 90% in 62.5% of patients, Topp notes.

Among 56 evaluable patients with DLBCL, the 53 who were exposed to glofitamab comprised the efficacy population, Topp adds. The combination elicited an overall response rate of 86.8% and a complete metabolic response rate of 75.5% in this population, Topp concludes.